News

FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED)
This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV.
MPR20h
Mavyret Indication Expanded to Include Treatment of Acute Hepatitis C Virus
Mavyret is a fixed dose combination of the direct-acting antiviral agents, glecaprevir, a HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.
Association of Schools and Programs of Public Health (ASPPH)21hOpinion
ASPPH-Led Congressional Briefing Marks Milestone in National Hepatitis C Elimination Effort
ASPPH proudly joined public health and medical leaders for a Congressional Briefing on the Hepatitis C Elimination Imperative ...
Stocktwits on MSN21h
AbbVie Stock Rises After FDA Approves Expanded Treatment Scope For Mavyret, But Retail Needs More To Cheer
Shares of AbbVie (ABBV) traded over 1% higher on Wednesday after the company announced that the U.S. Food and Drug ...
FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection
FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis ...